NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $4.48 -0.28 (-5.88%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$4.58 +0.11 (+2.34%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Lexeo Therapeutics Stock (NASDAQ:LXEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lexeo Therapeutics alerts:Sign Up Key Stats Today's Range$4.48▼$4.8050-Day Range$4.13▼$5.3752-Week Range$3.99▼$10.99Volume311,581 shsAverage Volume689,445 shsMarket Capitalization$367.58 millionP/E RatioN/ADividend YieldN/APrice Target$18.75Consensus RatingBuy Company Overview Lexeo Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders. The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings. To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy. Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide. AI Generated. May Contain Errors. Read More Lexeo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreLXEO MarketRank™: Lexeo Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 591st out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLexeo Therapeutics has a consensus price target of $18.75, representing about 318.5% upside from its current price of $4.48.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.18) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.47% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 19.77, which indicates bearish sentiment.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 20.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.95 News SentimentLexeo Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lexeo Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for LXEO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,817.00 in company stock.Percentage Held by Insiders2.00% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXEO Stock News HeadlinesLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by BrokeragesSeptember 9 at 3:58 AM | americanbankingnews.comLexeo Therapeutics to Participate in Upcoming Investor Conferences in SeptemberSeptember 2, 2026 | globenewswire.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.September 10 at 1:00 AM | Paradigm Press (Ad)Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 3,345 Shares of StockAugust 20, 2026 | insidertrades.comLexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020August 12, 2026 | quiverquant.comQLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsAugust 12, 2026 | globenewswire.comLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic CardiomyopathyAugust 5, 2026 | globenewswire.comLexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor FocusJuly 22, 2026 | tipranks.comSee More Headlines LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $9.93 on January 1st, 2026. Since then, LXEO shares have decreased by 54.9% and is now trading at $4.48. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released its earnings results on Wednesday, August, 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $127 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at $13.00-$15.00 per share. Who are Lexeo Therapeutics' major shareholders? Top institutional investors of Lexeo Therapeutics include Montanova Capital LLC (7.78%), BlackRock Inc. (7.31%), Frazier Life Sciences Management L.P. (5.88%) and Jupiter Topco LLC (5.04%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Jose Manuel Otero, Louis Edward Tamayo, Narinder Pal Bhalla, Eric Adler and Tai Sandi See. View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexeo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/12/2026Today9/10/20262026 Global Healthcare Conference9/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LXEO's financial health is in the Yellow zone, according to TradeSmith. LXEO has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year Founded2018Price Target and Rating Average Price Target for Lexeo Therapeutics$18.75 High Price Target$30.00 Low Price Target$9.00 Potential Upside/Downside+318.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$99.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.85% Return on Assets-38.03% Debt Debt-to-Equity RatioN/A Current Ratio13.89 Quick Ratio13.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book1.33Miscellaneous Outstanding Shares82,050,000Free Float80,405,000Market Cap$367.58 million OptionableNot Optionable Beta1.50 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:LXEO) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Three under-the-radar companies are already building the infrastructure behind a 200 billion government-backed...Eagle Publishing | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
